Hello Bio Announces Launch of Novel Adenosine Receptor Probes for Cancer & Cardiovascular Research
Hello Bio Announces Launch of Novel Adenosine Receptor Probes for Cancer & Cardiovascular Research
Hello Bio announces the launch of a novel cutting-edge range of adenosine receptor probes for cancer & cardiovascular research.
Hello Bio, a leading innovator in life sciences is proud to announce it has been granted a license from the Oncode Institute and Universiteit Leiden to commercialise and release a range of novel adenosine receptor probes, making them available for the first time to life science researchers worldwide.
Adenosine receptors (A1, A2A, A2B and A3) are GPCRs implicated in physiological and pathophysiological conditions such as cancer, immune and inflammatory conditions, and cardiac-ischaemic disease.
The Oncode Institute and Universiteit Leiden have developed a cutting-edge range of adenosine receptor compounds, composed of affinity-based probes (AfBP) and covalent binding ligands which will offer researchers new tools to advance the understanding of adenosine receptors. These include, LUF7909, which is a novel adenosine A1 receptor affinity-based probe which is suitable for click conjugation and use in applications such as confocal microscopy, SDS-PAGE and chemical proteomics profiling applications.
Other compounds include the novel, covalent affinity-based probe LUF7487 and covalent ligands LUF7746, LUF7745, LUF7982 and LUF7602.
We are thrilled to have been granted a licence from Oncode Institute and Universiteit Leiden to introduce this new range of adenosine probes to the research community. This collaboration reflects our ongoing commitment to provide scientists with novel tools and we believe these probes will provide new opportunities for the study of adenosine receptors, and improve understanding of these receptors in biological processes. These new compounds join Hello Bio’s unique range of adenosine receptor ligands which also include CA200634 CellAura fluorescent adenosine antagonist [XAC], CA200623 CellAura fluorescent adenosine agonist [NECA], A2A receptor antagonist ZM241385, and A2A receptor agonist CGS 21680. We look forward to seeing these novel adenosine compounds propel this exciting field of research forwards.
Steve Roome PhD, Managing Director and Founder, Hello Bio
The Oncode Institute Business Development team really helped me to identify partners potentially interested in the probes that we develop in Leiden. With their help, we were able to formalize our collaboration with Hello Bio and make our probes available to the field.
Laura Heitman PhD, Professor of Molecular Pharmacology at Leiden Academic Centre for Drug Research and Oncode Investigator
More information on these probes can be found here:
LUF7909 (HB4786): Novel, clickable Adenosine hA1AR Affinity-Based Probe (AfBP).
LUF7487 (HB9585): Novel, covalent Affinity-Based Probe (AfBP). Clickable antagonist for the A2AR.
LUF7746 (HB6921): The first covalent hA1AR partial agonist. Binds Irreversibly.
LUF7445 (HB8439): Novel, potent covalent A2A antagonist. Binds irreversibly.
LUF7982 (HB9905): Novel Selective A2B covalent ligand. Binds irreversibly.
LUF7602 (HB7286): Novel, potent, selective A3AR covalent antagonist
Contact
For more information, please contact
Steve Roome:
hello@hellobio.com
(0)117 318 0505
Further information
Hello Bio was founded by a team of experienced scientists and chemists who genuinely want to support life science research. Our aim is to offer a range of high quality life science tools at prices so low that as many researchers as possible will be able to afford them.
Hello Bio offers a range of agonists, antagonists, inhibitors, activators, antibodies and fluorescent tools at up to half the price of other suppliers. The range includes:
|